Lucia Lisi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7849688/publications.pdf

Version: 2024-02-01

471061 395343 1,180 34 17 33 h-index citations g-index papers 34 34 34 2168 all docs docs citations times ranked citing authors

#	Article	ΙF	CITATIONS
1	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacological Research, 2022, 175, 105997.	3.1	43
2	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.5	3
3	The effects of CHF6467, a new mutated form of NGF, on cell models of human glioblastoma. A comparison with wild-type NGF. Growth Factors, 2022, 40, 37-45.	0.5	2
4	Glioma-Associated Microglia Characterization in the Glioblastoma Microenvironment through a â€~Seed-and Soil' Approach: A Systematic Review. Brain Sciences, 2022, 12, 718.	1.1	8
5	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochemical Pharmacology, 2020, 180, 114169.	2.0	26
6	PDIA3 Expression in Glioblastoma Modulates Macrophage/Microglia Pro-Tumor Activation. International Journal of Molecular Sciences, 2020, 21, 8214.	1.8	25
7	PI3K/AKT/mTOR pathway in tumor progression of oligodendrogliomas. Translational Cancer Research, 2020, 9, 2161-2163.	0.4	1
8	DNA inhibitors for the treatment of brain tumors. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 195-207.	1.5	3
9	Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages. Oncology Reports, 2020, 43, 2083-2092.	1.2	10
10	Phospho-mTOR expression in human glioblastoma microglia-macrophage cells. Neurochemistry International, 2019, 129, 104485.	1.9	17
11	Pro-Inflammatory Activation of a New Immortalized Human Microglia Cell Line. Brain Sciences, 2019, 9, 111.	1.1	21
12	Transcriptome analysis of alcohol-treated microglia reveals downregulation of beta amyloid phagocytosis. Journal of Neuroinflammation, 2018, 15, 141.	3.1	34
13	Interactions between integrase inhibitors and human arginase 1. Journal of Neurochemistry, 2017, 142, 153-159.	2.1	4
14	Blockade of CCR5 receptor prevents M2 microglia phenotype in a microglia-glioma paradigm. Neurochemistry International, 2017, 108, 100-108.	1.9	43
15	The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 106.	3.5	36
16	Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS ONE, 2017, 12, e0187393.	1.1	11
17	Exploiting Microglial Functions for the Treatment of Glioblastoma. Current Cancer Drug Targets, 2017, 17, 267-281.	0.8	40
18	mTOR in Multiple Sclerosis. , 2016, , 331-343.		5

#	Article	IF	CITATIONS
19	Antiretrovirals inhibit arginase in human microglia. Journal of Neurochemistry, 2016, 136, 363-372.	2.1	15
20	mTOR Kinase: A Possible Pharmacological Target in the Management of Chronic Pain. BioMed Research International, 2015, 2015, 1-13.	0.9	54
21	The activation of type 1 corticotropin releasing factor receptor (CRF-R1) inhibits proliferation and promotes differentiation of neuroblastoma cells in vitro via p27Kip1 protein up-regulation and c-Myc mRNA down-regulation. Molecular and Cellular Endocrinology, 2015, 412, 205-215.	1.6	7
22	The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2015, 96, 11-16.	1.0	4
23	The mTOR kinase inhibitors polarize glioma-activated microglia to express a M1 phenotype. Journal of Neuroinflammation, 2014, 11, 125.	3.1	54
24	Proinflammatory-Activated Glioma Cells Induce a Switch in Microglial Polarization and Activation Status, From a Predominant M2b Phenotype to a Mixture of M1 and M2a/B Polarized Cells. ASN Neuro, 2014, 6, AN20130045.	1.5	67
25	Antiretroviral agents increase NO production in gp120/IFN \hat{i}^3 -stimulated cultures of rat microglia via an arginase-dependent mechanism. Journal of Neuroimmunology, 2014, 266, 24-32.	1.1	16
26	Tapentadol inhibits calcitonin gene-related peptide release from rat brainstem in vitro. Peptides, 2014, 56, 8-13.	1.2	9
27	mTOR kinase, a key player in the regulation of glial functions: Relevance for the therapy of multiple sclerosis. Glia, 2013, 61, 301-311.	2.5	82
28	The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE. Journal of Neuroimmunology, 2013, 255, 1-7.	1.1	8
29	Monocytes from Depressed Patients Display an Altered Pattern of Response to Endotoxin Challenge. PLoS ONE, 2013, 8, e52585.	1.1	22
30	Modulatory effects of the CCR5 antagonist maraviroc on microglial proâ€inflammatory activation elicited by gp120. Journal of Neurochemistry, 2012, 120, 106-114.	2.1	33
31	Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin- $\hat{\Pi}^2$ pro-inflammatory effects. Journal of Neuroimmunology, 2011, 237, 39-46.	1.1	44
32	The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. Journal of Neuroinflammation, $2011, 8, 1$.	3.1	139
33	Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochemical Pharmacology, 2009, 78, 1242-1251.	2.0	143
34	Proinflammatory-Activated Trigeminal Satellite Cells Promote Neuronal Sensitization: Relevance for Migraine Pathology. Molecular Pain, 2009, 5, 1744-8069-5-43.	1.0	151